Ying Sun1, Ehrentraud J Eichelbaum, Hai Wang, David L Vesely. 1. Department of Internal Medicine, University of South Florida Cardiac Hormone Center and James A. Haley Veterans Medical Center Tampa, Florida 33612, USA.
Abstract
BACKGROUND: Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas. MATERIALS AND METHODS: Vessel dilator, kaliuretic peptide and cyclic GMP's effects on ERK 1/2 kinase were examined in human prostate adenocarcinoma cells. RESULTS: Vessel dilator and kaliuretic peptide decreased the activation of ERK 1/2 over a concentration range of 0.01 microM to 1 microM. Vessel dilator and kaliuretic peptide (each 1 microM) inhibited the phosphorylation of ERK 1/2 kinase 96% (p < 0.0001) and 70% (p < 0.001), respectively. Both had significant effects within five minutes at their 0.01 microM concentrations. The inhibition of ERK 1/2 lasted for at least two hours secondary to both. Their ability to inhibit ERK 1/2 was decreased by cyclic GMP antibody and cyclic GMP itself decreased ERK 1/2 phosphorylation. CONCLUSION: Vessel dilator and kaliuretic peptide both inhibit ERK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action.
BACKGROUND: Vessel dilator and kaliuretic peptide have anticancer effects in humanprostate adenocarcinomas. MATERIALS AND METHODS: Vessel dilator, kaliuretic peptide and cyclic GMP's effects on ERK 1/2 kinase were examined in humanprostate adenocarcinoma cells. RESULTS: Vessel dilator and kaliuretic peptide decreased the activation of ERK 1/2 over a concentration range of 0.01 microM to 1 microM. Vessel dilator and kaliuretic peptide (each 1 microM) inhibited the phosphorylation of ERK 1/2 kinase 96% (p < 0.0001) and 70% (p < 0.001), respectively. Both had significant effects within five minutes at their 0.01 microM concentrations. The inhibition of ERK 1/2 lasted for at least two hours secondary to both. Their ability to inhibit ERK 1/2 was decreased by cyclic GMP antibody and cyclic GMP itself decreased ERK 1/2 phosphorylation. CONCLUSION: Vessel dilator and kaliuretic peptide both inhibit ERK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action.
Authors: Meghan L Lane; Chelsea D Frost; Jennifer P Nguyen; William P Skelton; Michelle Skelton; David L Vesely Journal: Mol Cell Biochem Date: 2012-09-11 Impact factor: 3.396
Authors: Ehrentraud J Eichelbaum; Brian A Vesely; Abdel A Alli; Ying Sun; William R Gower; David L Vesely Journal: Endocrine Date: 2006-12 Impact factor: 3.925
Authors: Maha E Houssen; Hayam F Ghazy; Kamel Farag; Mona Abo Bakr El-Hussiny; Mohamed A El Ghaffar; Sahar Alsayed Mohamed Alsayed; Omar Farouk Journal: Contemp Oncol (Pozn) Date: 2017-03-22